This study provides a novel immunotherapy strategy for patients with squamous non-small cell lung cancer (sqNSCLC) who have progressed after chemotherapy, suggesting that CTLA-4-targeted agents may offer advantages in specific tumor microenvironments. It holds significant reference value for the design of clinical trials targeting immunotherapy-resistant populations.
Literature Overview
This article, titled 'Gotistobart or docetaxel in metastatic squamous non-small cell lung cancer: stage 1 of the randomized phase 3 PRESERVE-003 trial,' published in the journal Nature Medicine, systematically investigates the efficacy and safety of the novel pH-sensitive CTLA-4 antibody gotistobart compared to docetaxel in patients with metastatic squamous non-small cell lung cancer (sqNSCLC) who have become resistant to PD-(L)1 inhibitors and chemotherapy. Using a randomized controlled design, the study reveals for the first time a survival benefit associated with a selective tumor microenvironment Treg depletion strategy, providing critical evidence for future clinical development.Background Knowledge
Lung cancer remains the leading cause of cancer-related deaths worldwide, and the sqNSCLC subtype has a particularly poor prognosis. After progression on PD-(L)1 inhibitors and platinum-based chemotherapy, treatment options are extremely limited. The current standard second-line regimen, docetaxel, offers only modest efficacy, with a median overall survival of just 8–9.4 months, and significant toxicity, leaving a major unmet clinical need. Although CTLA-4, as the first immune checkpoint target, has been successfully used in melanoma, its application in NSCLC has been limited by systemic toxicity and insufficient efficacy. Traditional antibodies such as ipilimumab have failed to demonstrate a survival advantage in treatment-refractory sqNSCLC. This study introduces gotistobart, a pH-sensitive CTLA-4 antibody designed to selectively bind and deplete regulatory T cells (Tregs) within the acidic tumor microenvironment, thereby enhancing anti-tumor immunity while minimizing systemic toxicity. This mechanism relies on the synergistic action of high intratumoral CTLA-4 expression and an acidic environment, offering a novel approach to overcome the limitations of conventional CTLA-4 therapies.
Research Methods and Experiments
The study employed a multicenter, multinational, open-label, randomized phase II design, enrolling 91 patients with metastatic sqNSCLC who were randomly assigned to receive either gotistobart (6 mg/kg, with a loading dose) or docetaxel (75 mg/m²). The primary endpoint was overall survival (OS), with secondary endpoints including progression-free survival (PFS), objective response rate (ORR), and safety. All patients had histologically confirmed disease and had previously undergone treatment with both PD-(L)1 inhibitors and platinum-based chemotherapy, representing a real-world, treatment-refractory population. Tumor assessments were conducted using RECIST 1.1 criteria, and survival curves were analyzed using the Kaplan-Meier method to ensure robust results.Key Conclusions and Perspectives
Research Significance and Prospects
This study redefines the role of CTLA-4-targeted therapy in NSCLC, emphasizing the importance of tumor microenvironment selectivity. Compared to traditional CTLA-4 antibodies, gotistobart achieves selective Treg depletion via a pH-dependent mechanism, enhancing efficacy while mitigating toxicity, thus establishing a new paradigm for drug design. Its significant survival advantage in sqNSCLC suggests that histology may serve as a predictive factor for immunotherapy response, advancing the field of precision immunotherapy.
Conclusion
This study marks a pivotal step in the treatment of refractory sqNSCLC, shifting from traditional chemotherapy toward mechanism-driven immunotherapy. As the first CTLA-4 monotherapy to demonstrate a survival benefit in a phase III trial, gotistobart not only validates the central role of regulatory T cells in immunosuppressive microenvironments but also offers a new therapeutic option for patients resistant to PD-(L)1 inhibitors. Its unique pH-sensitive mechanism provides a blueprint for the design of next-generation immune checkpoint inhibitors. Future integration of biomarkers such as tumor mutational burden, Treg density, or PTEN status may enable more precise patient stratification. From bench to bedside, this study strengthens the translational value of tumor microenvironment-targeted strategies and lays the foundation for developing more effective combination immunotherapies, potentially reshaping the standard of care for sqNSCLC.
